We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

New Blood Test Highly Accurate in Screening for Alzheimer’s

By LabMedica International staff writers
Posted on 04 Sep 2023
Print article
Image: A new blood test has shown promise as an Alzheimer\'s disease biomarker (Photo courtesy of Freepik)
Image: A new blood test has shown promise as an Alzheimer\'s disease biomarker (Photo courtesy of Freepik)

Researchers have made substantial efforts in recent years towards developing blood-based biomarkers that could potentially aid in the detection of Alzheimer's disease (AD). The key focus has been on the tau protein, particularly its phosphorylated form (p-tau), which is a significant player in AD pathology. These new blood-based p-tau biomarkers, especially one variant known as p-tau217, have displayed significant potential as valuable tools for screening individuals with memory issues or early cognitive symptoms hinting at early-stage AD. Despite its strong promise, there has been a concern that categorizing early-stage patients as either having "AD or not AD" could still yield a relatively high rate of false positives (positive test results in individuals without AD) and false negatives (negative test results in individuals who are later confirmed to have AD based on other assessments like amyloid PET scans).

Researchers from the University of Gothenburg (Gothenburg, Sweden), together with colleagues at University of Lund (Lund, Sweden), have developed an innovative strategy for the clinical implementation of blood biomarkers. Their strategy was designed after taking into account the ethical and psychological concerns arising from possible misdiagnoses, as well as the substantial costs and potential medical risks involved in initiating treatments for individuals who don't have the actual target disease. Their novel blood test, named p-tau217, has demonstrated potential as an Alzheimer's disease biomarker. Moreover, when employed in a two-step workflow, the test has shown impressive accuracy in either identifying or excluding brain amyloidosis, which is a critical and early pathology.

In the two-step model, the first step involves a diagnostic model (utilizing plasma p-tau217 along with age and APOE e4) to categorize patients with mild cognitive impairment (MCI) based on their risk of amyloid PET positivity. The second step involves confirmatory testing using CSF Ab42/40 ratio (or amyloid EPT), exclusively for those with uncertain outcomes in step 1. This framework was assessed using 348 MCI participants from the Swedish BioFINDER studies and then validated through the independent TRIAD cohort, utilizing an independent method for plasma p-tau217 analysis.

The researchers evaluated the model at three different thresholding strategies to classify participants into low, intermediate, and high-risk groups for being "Aβ positive" (indicating AD-type pathology). The use of stringent lower probability thresholds with 97.5% sensitivity (to avoid missing Aβ positive patients) revealed merely 6.6% false negatives. Conversely, adopting a stringent 97.5% specificity (to prevent categorizing Aβ negative patients as 'high risk') yielded merely 2.3% false positives. At these stringent sensitivity/specificity thresholds, around 41% of patients fell into the intermediate risk category (in contrast to 29% of patients for the 95% thresholds). Further analysis of this group using CSF Aβ42/40 demonstrated strong concordance (86%) with amyloid PET outcomes. These results were confirmed in the independent McGill patient cohort.

Thus, the study introduced a blood plasma p-tau217-based two-step model for stratifying MCI patients into high, low, and intermediate-risk categories for brain amyloidosis and early AD pathology. The application of the blood test in step 1 showed exceptional accuracy in identifying high-risk patients. Depending on the clinical context, these patients could either receive a diagnosis and commence symptomatic treatments or be referred to specialized clinics for starting potential disease-modifying treatments in the future. For the low-risk group, AD could be confidently ruled out. The intermediate-risk group will encompass only about one-third of patients, substantially reducing the need for confirmatory CSF or PET testing at specialized clinics and leading to cost savings for society. According to the researchers, this two-step model presents a clinically valuable approach for utilizing the p-tau217 blood test in AD screening.

Related Links:
University of Gothenburg 
University of Lund 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article


Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.